Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen-Reference-Cited by-同舟云学术

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen

Published:2006-05 Issue:5 Volume:12 Page:573-584
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Deeg H. Joachim,Storer Barry E.,Boeckh Michael,Martin Paul J.,McCune Jeannine S.,Myerson David,Heimfeld Shelly,Flowers Mary E.,Anasetti Claudio,Doney Kristine C.,Hansen John A.,Kiem Hans-Peter,Nash Richard A.,O’Donnell Paul V.,Radich Jerald P.,Sandmaier Brenda M.,Scott Bart L.,Sorror Mohamed L.,Warren E. Houston,Witherspoon Robert P.,Woolfrey Ann,Appelbaum Frederick R.,Storb Rainer

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference40 articles.

1. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome;Deeg;Blood,2002

2. Once-daily intravenous busulfan and fludarabine;de Lima;Blood,2004

3. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes;Guardiola;Blood,2002

4. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation;Nevill;Blood,1998

5. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia;Sierra;Blood,2002

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation;Annals of Hematology;2023-12-29

2. Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis;PLOS ONE;2023-04-18

3. Role of Anti-thymocyte Globulin in Stem Cell Transplant;Basics of Hematopoietic Stem Cell Transplant;2023

4. ATG or no ATG? – survey of clinical practice in EBMT centers on behalf of the Transplant Complications Working Party of EBMT;Bone Marrow Transplantation;2022-12-05

5. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors;Transplantation and Cellular Therapy;2022-11